Triazole- and Tetrazole-Bridged Nucleic Acids: Synthesis, Duplex Stability, Nuclease Resistance, and in Vitro and in Vivo Antisense Potency

Antisense oligonucleotides are attractive therapeutic agents for several types of disease. One of the most promising modifications of antisense oligonucleotides is the introduction of bridged nucleic acids. As we report here, we designed novel bridged nucleic acids, triazole-bridged nucleic acid (Tr...

Full description

Saved in:
Bibliographic Details
Published inJournal of organic chemistry Vol. 82; no. 1; pp. 12 - 24
Main Authors Mitsuoka, Yasunori, Yamamoto, Tsuyoshi, Kugimiya, Akira, Waki, Reiko, Wada, Fumito, Tahara, Saori, Sawamura, Motoki, Noda, Mio, Fujimura, Yuko, Kato, Yuki, Hari, Yoshiyuki, Obika, Satoshi
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 06.01.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Antisense oligonucleotides are attractive therapeutic agents for several types of disease. One of the most promising modifications of antisense oligonucleotides is the introduction of bridged nucleic acids. As we report here, we designed novel bridged nucleic acids, triazole-bridged nucleic acid (TrNA), and tetrazole-bridged nucleic acid (TeNA), whose sugar conformations are restricted to N-type by heteroaromatic ring-bridged structures. We then successfully synthesized TrNA and TeNA and introduced these monomers into oligonucleotides. In UV-melting experiments, TrNA-modified oligonucleotides exhibited increased binding affinity toward complementary RNA and decreased binding affinity toward complementary DNA, although TeNA-modified oligonucleotides were decomposed under the annealing conditions. Enzymatic degradation experiments demonstrated that introduction of TrNA at the 3′-terminus rendered oligonucleotides resistant to nuclease digestion. Furthermore, we tested the silencing potencies of TrNA-modified antisense oligonucleotides using in vitro and in vivo assays. These experiments revealed that TrNA-modified antisense oligonucleotides induced potent downregulation of gene expression in liver. In addition, TrNA-modified antisense oligonucleotides showed a tendency for increased liver biodistribution. Taken together, our findings indicate that TrNA is a good candidate for practical application in antisense methodology.
AbstractList Antisense oligonucleotides are attractive therapeutic agents for several types of disease. One of the most promising modifications of antisense oligonucleotides is the introduction of bridged nucleic acids. As we report here, we designed novel bridged nucleic acids, triazole-bridged nucleic acid (TrNA), and tetrazole-bridged nucleic acid (TeNA), whose sugar conformations are restricted to N-type by heteroaromatic ring-bridged structures. We then successfully synthesized TrNA and TeNA and introduced these monomers into oligonucleotides. In UV-melting experiments, TrNA-modified oligonucleotides exhibited increased binding affinity toward complementary RNA and decreased binding affinity toward complementary DNA, although TeNA-modified oligonucleotides were decomposed under the annealing conditions. Enzymatic degradation experiments demonstrated that introduction of TrNA at the 3'-terminus rendered oligonucleotides resistant to nuclease digestion. Furthermore, we tested the silencing potencies of TrNA-modified antisense oligonucleotides using in vitro and in vivo assays. These experiments revealed that TrNA-modified antisense oligonucleotides induced potent downregulation of gene expression in liver. In addition, TrNA-modified antisense oligonucleotides showed a tendency for increased liver biodistribution. Taken together, our findings indicate that TrNA is a good candidate for practical application in antisense methodology.
Author Obika, Satoshi
Sawamura, Motoki
Wada, Fumito
Hari, Yoshiyuki
Fujimura, Yuko
Waki, Reiko
Noda, Mio
Kugimiya, Akira
Tahara, Saori
Mitsuoka, Yasunori
Yamamoto, Tsuyoshi
Kato, Yuki
AuthorAffiliation Faculty of Pharmaceutical Sciences
Discovery Research Laboratory for Innovative Frontier Medicines
Research Laboratory for Development
Tokushima Bunri University
Osaka University
Shionogi & Co., Ltd
Graduate School of Pharmaceutical Sciences
AuthorAffiliation_xml – name: Discovery Research Laboratory for Innovative Frontier Medicines
– name: Research Laboratory for Development
– name: Tokushima Bunri University
– name: Osaka University
– name: Graduate School of Pharmaceutical Sciences
– name: Faculty of Pharmaceutical Sciences
– name: Shionogi & Co., Ltd
Author_xml – sequence: 1
  givenname: Yasunori
  surname: Mitsuoka
  fullname: Mitsuoka, Yasunori
– sequence: 2
  givenname: Tsuyoshi
  surname: Yamamoto
  fullname: Yamamoto, Tsuyoshi
– sequence: 3
  givenname: Akira
  surname: Kugimiya
  fullname: Kugimiya, Akira
  email: akira.kugimiya@shionogi.co.jp
– sequence: 4
  givenname: Reiko
  surname: Waki
  fullname: Waki, Reiko
– sequence: 5
  givenname: Fumito
  surname: Wada
  fullname: Wada, Fumito
– sequence: 6
  givenname: Saori
  surname: Tahara
  fullname: Tahara, Saori
– sequence: 7
  givenname: Motoki
  surname: Sawamura
  fullname: Sawamura, Motoki
– sequence: 8
  givenname: Mio
  surname: Noda
  fullname: Noda, Mio
– sequence: 9
  givenname: Yuko
  surname: Fujimura
  fullname: Fujimura, Yuko
– sequence: 10
  givenname: Yuki
  surname: Kato
  fullname: Kato, Yuki
– sequence: 11
  givenname: Yoshiyuki
  surname: Hari
  fullname: Hari, Yoshiyuki
– sequence: 12
  givenname: Satoshi
  orcidid: 0000-0002-6842-6812
  surname: Obika
  fullname: Obika, Satoshi
  email: obika@phs.osaka-u.ac.jp
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27936689$$D View this record in MEDLINE/PubMed
BookMark eNp1kUFv1DAQhS1URLelZ27IRyQ2W9uxnYTbUmipVLWoXbhGjj1pXWXtxXYQy1_gT9cl23JiLqMnfe9JM-8A7TnvAKE3lCwoYfRY6bi493ohO8I4rV6gGRWMFLIhfA_NCGGsKJks99FBjPckjxDiFdpnVVNKWTcz9GcVrPrtByiwcgavIIVJfgzW3ILBl6MewGq81NbED_hm69IdRBvn-NO4GeAXvkmqs4NN2_nEqgj4-pFIymmY_421Dn-3Kfh_4qfHS5dsBJfxrz6B09vX6GWvhghHu32Ivp1-Xp18KS6uzs5PlheFKpsmFX1JTGcohV5WNWdcCK4013WnmRFVRSot-7rnisiuEsyoqmMNU8awssxWxstD9G7K3QT_Y4SY2rWNGoZBOfBjbGktmBQNlyyjxxOqg48xQN9ugl2rsG0paR8baHMDbW6g3TWQHW934WO3BvPMP708A-8nYHKOweVb_xv3AAL4k_c
CitedBy_id crossref_primary_10_1021_acs_orglett_0c01780
crossref_primary_10_3390_biomedicines9060628
crossref_primary_10_1016_j_carres_2024_109126
crossref_primary_10_3390_molecules27238379
crossref_primary_10_1002_ejoc_202300946
crossref_primary_10_3762_bjoc_13_205
crossref_primary_10_1039_C7OB00698E
crossref_primary_10_1016_j_tetlet_2020_151708
crossref_primary_10_1021_acs_joc_2c01582
crossref_primary_10_1002_ajoc_202000479
Cites_doi 10.1016/S0040-4039(97)10322-7
10.1016/j.tetlet.2010.02.034
10.1039/b201557a
10.1021/jm801294h
10.1021/jo901009w
10.1016/S0040-4039(98)01084-3
10.1002/anie.201300555
10.1021/jo9814445
10.1016/j.ejphar.2013.11.004
10.1002/cbic.201200669
10.1002/cbic.201200506
10.1039/C4MD00184B
10.1016/S0960-894X(98)00366-7
10.1016/j.tetlet.2006.12.046
10.1039/9781849731102-00328
10.4155/fmc.11.2
10.1016/S0040-4020(98)00094-5
10.1002/cmdc.201000539
10.1002/anie.196306331
10.1039/c2cc32286b
10.1021/jm000209n
10.1016/0040-6031(89)85139-1
10.1007/s12265-013-9495-7
10.1107/S0567740879006567
10.1021/jo701914y
10.1021/jo902560f
10.1021/jo8016742
10.1021/ja038481k
10.1038/mtna.2012.16
10.1021/ja0177814
10.1021/ol902681t
10.1039/a708608c
10.1021/ja071106y
10.1161/01.ATV.0000066131.01313.EB
10.3987/REV-10-667
10.1039/C5OB00242G
10.1002/9783527621286.ch5
10.3791/3917
10.1021/jo801927k
10.1039/C3CC46017G
10.1021/bi0485732
10.1021/ol8003657
10.1021/ja105875e
ContentType Journal Article
Copyright Copyright © 2016 American Chemical Society
Copyright_xml – notice: Copyright © 2016 American Chemical Society
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1021/acs.joc.6b02417
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
EISSN 1520-6904
EndPage 24
ExternalDocumentID 10_1021_acs_joc_6b02417
27936689
a8803110
Genre Journal Article
GroupedDBID -
.K2
29L
53G
55A
5RE
5VS
7~N
85S
AABXI
ABFLS
ABMVS
ABPPZ
ABPTK
ABUCX
ABUFD
ACGFS
ACJ
ACNCT
ACS
AEESW
AENEX
AFEFF
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
BAANH
CJ0
CS3
D0L
DU5
DZ
EBS
ED
ED~
EJD
F20
F5P
GNL
IH9
IHE
JG
JG~
K2
LG6
P2P
PZZ
ROL
RXW
TAE
TN5
UI2
UKR
UPT
VF5
VG9
VQA
W1F
WH7
X
XFK
YZZ
---
-DZ
-~X
4.4
AAHBH
ABJNI
ABQRX
ACBEA
ACGFO
ADHLV
AGXLV
AHGAQ
CGR
CUPRZ
CUY
CVF
ECM
EIF
GGK
IH2
NPM
TAF
XSW
YQT
ZCA
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-a399t-f30dbd11ef678424554ac4c8bc2d57707c6f8f4a06b752da7b292add233f30243
IEDL.DBID ACS
ISSN 0022-3263
IngestDate Fri Aug 16 10:29:23 EDT 2024
Fri Aug 23 03:28:48 EDT 2024
Sat Sep 28 07:59:38 EDT 2024
Thu Aug 27 13:42:11 EDT 2020
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a399t-f30dbd11ef678424554ac4c8bc2d57707c6f8f4a06b752da7b292add233f30243
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-6842-6812
PMID 27936689
PQID 1852659462
PQPubID 23479
PageCount 13
ParticipantIDs proquest_miscellaneous_1852659462
crossref_primary_10_1021_acs_joc_6b02417
pubmed_primary_27936689
acs_journals_10_1021_acs_joc_6b02417
ProviderPackageCode JG~
55A
AABXI
GNL
VF5
7~N
ACJ
VG9
W1F
ACS
AEESW
AFEFF
.K2
ABMVS
ABUCX
IH9
BAANH
AQSVZ
ED~
UI2
PublicationCentury 2000
PublicationDate 2017-01-06
PublicationDateYYYYMMDD 2017-01-06
PublicationDate_xml – month: 01
  year: 2017
  text: 2017-01-06
  day: 06
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of organic chemistry
PublicationTitleAlternate J. Org. Chem
PublicationYear 2017
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References Schlingensiepen R. (ref3/cit3) 1997
ref9/cit9
ref45/cit45
ref6/cit6
ref36/cit36
ref27/cit27
ref18/cit18
ref11/cit11
ref25/cit25
ref16/cit16
ref29/cit29
ref32/cit32
ref23/cit23
ref39/cit39
ref14/cit14
ref8/cit8
ref5/cit5
ref31/cit31
ref43/cit43
Stein C. A. (ref2/cit2) 1998
ref34/cit34
ref37/cit37
ref28/cit28
ref40/cit40
ref20/cit20
ref17/cit17
ref10/cit10
ref26/cit26
ref35/cit35
ref19/cit19
ref21/cit21
ref12/cit12
ref15/cit15
ref42/cit42
ref46/cit46
ref41/cit41
ref22/cit22
ref13/cit13
ref33/cit33
ref4/cit4
ref30/cit30
ref1/cit1
ref24/cit24
ref38/cit38
ref44/cit44
ref7/cit7
References_xml – ident: ref8/cit8
  doi: 10.1016/S0040-4039(97)10322-7
– ident: ref29/cit29
  doi: 10.1016/j.tetlet.2010.02.034
– ident: ref6/cit6
  doi: 10.1039/b201557a
– ident: ref17/cit17
  doi: 10.1021/jm801294h
– volume-title: Applied Antisense Oligonucleotide Technology
  year: 1998
  ident: ref2/cit2
  contributor:
    fullname: Stein C. A.
– ident: ref15/cit15
  doi: 10.1021/jo901009w
– ident: ref9/cit9
  doi: 10.1016/S0040-4039(98)01084-3
– ident: ref16/cit16
  doi: 10.1002/anie.201300555
– ident: ref13/cit13
  doi: 10.1021/jo9814445
– ident: ref33/cit33
  doi: 10.1016/j.ejphar.2013.11.004
– volume-title: Antisense- from Technology to Therapy
  year: 1997
  ident: ref3/cit3
  contributor:
    fullname: Schlingensiepen R.
– ident: ref22/cit22
  doi: 10.1002/cbic.201200669
– ident: ref23/cit23
  doi: 10.1002/cbic.201200506
– ident: ref5/cit5
  doi: 10.1039/C4MD00184B
– ident: ref14/cit14
  doi: 10.1016/S0960-894X(98)00366-7
– ident: ref40/cit40
  doi: 10.1016/j.tetlet.2006.12.046
– ident: ref25/cit25
  doi: 10.1039/9781849731102-00328
– ident: ref4/cit4
  doi: 10.4155/fmc.11.2
– ident: ref11/cit11
  doi: 10.1016/S0040-4020(98)00094-5
– ident: ref27/cit27
  doi: 10.1002/cmdc.201000539
– ident: ref37/cit37
  doi: 10.1002/anie.196306331
– ident: ref34/cit34
– ident: ref42/cit42
  doi: 10.1039/c2cc32286b
– ident: ref26/cit26
  doi: 10.1021/jm000209n
– ident: ref41/cit41
  doi: 10.1016/0040-6031(89)85139-1
– ident: ref1/cit1
  doi: 10.1007/s12265-013-9495-7
– ident: ref31/cit31
  doi: 10.1107/S0567740879006567
– ident: ref39/cit39
  doi: 10.1021/jo701914y
– ident: ref18/cit18
  doi: 10.1021/jo902560f
– ident: ref20/cit20
  doi: 10.1021/jo8016742
– ident: ref28/cit28
  doi: 10.1021/ja038481k
– ident: ref46/cit46
  doi: 10.1038/mtna.2012.16
– ident: ref35/cit35
  doi: 10.1021/ja0177814
– ident: ref36/cit36
  doi: 10.1021/ol902681t
– ident: ref10/cit10
  doi: 10.1039/a708608c
– ident: ref19/cit19
  doi: 10.1021/ja071106y
– ident: ref32/cit32
  doi: 10.1161/01.ATV.0000066131.01313.EB
– ident: ref7/cit7
  doi: 10.3987/REV-10-667
– ident: ref24/cit24
  doi: 10.1039/C5OB00242G
– ident: ref44/cit44
  doi: 10.1002/9783527621286.ch5
– ident: ref45/cit45
  doi: 10.3791/3917
– ident: ref30/cit30
  doi: 10.1021/jo801927k
– ident: ref43/cit43
  doi: 10.1039/C3CC46017G
– ident: ref12/cit12
  doi: 10.1021/bi0485732
– ident: ref38/cit38
  doi: 10.1021/ol8003657
– ident: ref21/cit21
  doi: 10.1021/ja105875e
SSID ssj0000555
Score 2.327149
Snippet Antisense oligonucleotides are attractive therapeutic agents for several types of disease. One of the most promising modifications of antisense...
SourceID proquest
crossref
pubmed
acs
SourceType Aggregation Database
Index Database
Publisher
StartPage 12
SubjectTerms Deoxyribonucleases - chemistry
Deoxyribonucleases - metabolism
DNA, Complementary - chemistry
Humans
Nucleic Acid Conformation
Nucleic Acids - chemical synthesis
Nucleic Acids - chemistry
Oligonucleotides, Antisense - chemistry
RNA, Complementary - chemistry
Tetrazoles - chemical synthesis
Tetrazoles - chemistry
Title Triazole- and Tetrazole-Bridged Nucleic Acids: Synthesis, Duplex Stability, Nuclease Resistance, and in Vitro and in Vivo Antisense Potency
URI http://dx.doi.org/10.1021/acs.joc.6b02417
https://www.ncbi.nlm.nih.gov/pubmed/27936689
https://search.proquest.com/docview/1852659462
Volume 82
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT9wwELYoHNpLeZSWLQ-5EoceNtvE8SPmtiwghFSEyoK4RY7tSCnIQZts1eUv8KcZJ_tQixAcE00mlj3298XjfIPQPpEiYkaEQaK4DmhiZSBDamAxhC8xQCzAOL818POcn17Rsxt2sxCL_j-DT6IfSle936Xu8QzgJBLv0AoRMDU8CxpcLhZdxthcGJzweK7i88yBhyFd_QtDL3DLBmNOVtvTWVUjTeiPltz2xnXW0w_PhRtfb_4a-jhlmrjfhsY6WrJuA70fzAq8fUKPQwi-h_LOBlg5g4e2HrWXh81PXAafe63jQuO-Lkx1gC8nDthiVVRdfDS-v7N_MTDV5mztpNvaAiLiX96i9rHUbdwWDl8X9ahcXPwpcd_5GtAOzC9KT9onm-jq5Hg4OA2mtRkCBZSmDvI4NJmJIpsD2vnsKaNKU51kmhgmRCg0z5OcqpBnghGjREYkgbWUxDE8Smj8GS270tkthEOWZ0RI4H7G0jAx0kpJ8zBWEYcXaNFB-9CJ6XRuVWmTNidR2t7U6bRnO-j7bETT-1ap42XTb7MRT6HPfYpEOVuOwXfiywVIykkHfWlDYe4M2hhznsivb2vPNvpAPAXw2zV8By3Xo7HdBQJTZ3tN6D4B3pXpGg
link.rule.ids 315,783,787,2772,27088,27936,27937,57066,57116
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB6VcigXKO-FAkbqgcNmSRw_4t6WhWqBdgV0i3qLEtuRApVTbbKI7V_gT3ec7EOAKsEx1mQysSf-vnjsGYB9qmTEjQyDJBM6YIlVgQqZwckQ_8QQsRDj_NLA8USMT9mHM362BeHqLAwaUaOmug3ib7ILRK9927dKD0SOqBLJG3CTS4RLT4ZGJ5u5l3O-zg9ORbxO5vOXAo9Guv4dja6hmC3UHN6Bz2sj2x0m3wfzJh_oyz_yN_7PW-zC7SXvJMPOUe7ClnX3YGe0Kvd2H35N0RUvq3MbkMwZMrXNrLt80x7pMmTiMx-Xmgx1aeoDcrJwyB3rsu6Tt_OLc_uTIG9td9ou-p0s4iP54iUa71n9Vm3pyNeymVWbix8VGTpfEdqh-KfKU_jFAzg9fDcdjYNlpYYgQ4LTBEUcmtxEkS0Q-3wslbNMM53kmhouZSi1KJKCZaHIJacmkzlVFGdWGsd4K2XxQ9h2lbOPgYS8yKlUyASNZWFilFWKFWGcRQIfoGUP9rET0-WXVqdtEJ1Gadeo02XP9uDVamDTiy5vx_WiL1cDn2Kf-4BJ5mw1R92JLx6gmKA9eNR5xFoZ2hgLkagn_2bPC9gZT4-P0qP3k49P4Rb15MAv5Ig92G5mc_sMqU2TP2-9-QpoA_F_
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bb9MwFLbGJgEvsHEtMDDSHnhoSuL4EvNWulUbl2piLdpblNiOFJicqkkR3V_gT3PspJ0GmgSPtk5OHPvY3xcf-xyEDogUEdMiDJKMq4AmRgYypBoWQ_gTA8QCjHNbA58n_HhGP5yz8-5SmLsLA42oQVPtnfhuVs910UUYiN66-m-VGvAckCUSt9AOE5F3zg5HZ1frL2NsEyOc8HgT0OcvBQ6RVH0dkW6gmR5uxvfRbNNQf8rk-2DZ5AN1-UcMx__9kl10r-OfeNgazB7aMvYBujNap317iH5NwSQvqwsT4MxqPDXNoi2-91e7NJ64CMilwkNV6vodPltZ4JB1Wffx4XJ-YX5i4K_-xO2q38oCTuIvTqJxFtb3akuLv5bNoroq_Kjw0LrM0BbETytH5VeP0Gx8NB0dB13GhiADotMERRzqXEeRKQADnU-V0UxRleSKaCZEKBQvkoJmIc8FIzoTOZEEVlgSx_AoofFjtG0ra54iHLIiJ0ICI9SGhomWRkpahHEWcXiBEj10AJ2YdjOuTr0znURpW6nSrmd76M16cNN5G7_jZtHX68FPoc-d4ySzplqC7sQlEZCUkx560lrFRhm0MeY8kc_-rT2v0O3Tw3H66WTy8Tm6SxxHcPs5_AXabhZLsw8Mp8lfeoP-DTL68_k
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Triazole-+and+Tetrazole-Bridged+Nucleic+Acids%3A+Synthesis%2C+Duplex+Stability%2C+Nuclease+Resistance%2C+and+in+Vitro+and+in+Vivo+Antisense+Potency&rft.jtitle=Journal+of+organic+chemistry&rft.au=Mitsuoka%2C+Yasunori&rft.au=Yamamoto%2C+Tsuyoshi&rft.au=Kugimiya%2C+Akira&rft.au=Waki%2C+Reiko&rft.date=2017-01-06&rft.pub=American+Chemical+Society&rft.issn=0022-3263&rft.eissn=1520-6904&rft.volume=82&rft.issue=1&rft.spage=12&rft.epage=24&rft_id=info:doi/10.1021%2Facs.joc.6b02417&rft.externalDocID=a8803110
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3263&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3263&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3263&client=summon